GHRP-2
200–300 mcg · 2-3×/day
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 2 cited sources
Evidence
- Human Studies
- 10
- Animal Studies
- 20
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Limited — early pharmaceutical development data only, program not carried to approval
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
GHRP-2 is a synthetic hexapeptide ghrelin-receptor agonist that stimulates GH release, with a moderate effect on appetite and a smaller cortisol/prolactin rise than hexarelin but more than ipamorelin. It has undergone some early-phase pharmaceutical development but was not carried to approval.
Common Protocols
- 200–300 mcg subcutaneous, 2-3x daily, commonly stacked with a GHRH analogue like CJC-1295
Side Effects
- Increased hunger
- Injection site reaction
- Mild water retention
- Modest cortisol/prolactin elevation
Interactions
- Combining with other GH secretagogues compounds both effect and risk
Practical Details
- Cost
- $
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution
Key Studies & Reviews
- Bowers CY, Granda-Ayala R (1996). GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab. PMID 8887169.
- Ghigo E et al. (1997). Growth hormone-releasing peptides. Eur J Endocrinol. PMID 9186261.
Search the Research
GHRP-2 FAQ
What is the typical GHRP-2 dosage?
Commonly reported protocols: 200–300 mcg subcutaneous, 2-3x daily, commonly stacked with a GHRH analogue like CJC-1295. Our reference entry uses 200–300 mcg, 2-3×/day. These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of GHRP-2?
Reported side effects include: Increased hunger; Injection site reaction; Mild water retention; Modest cortisol/prolactin elevation.
Is GHRP-2 FDA approved?
GHRP-2 is not FDA approved for human use and is generally sold as a research chemical, so purity and dosing are not regulated.
How much research is there on GHRP-2?
Our evidence profile counts roughly 10 human and 20 animal studies, with low overall confidence. Long-term safety: Limited — early pharmaceutical development data only, program not carried to approval.
Does GHRP-2 interact with other drugs or supplements?
Combining with other GH secretagogues compounds both effect and risk.
How do I reconstitute GHRP-2?
A common setup is a 5 mg vial mixed with 2 mL of bacteriostatic water, which puts a 200–300 mcg dose at about 8 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution.
Related compounds
GH secretagogue; moderate appetite stimulation, often paired with CJC-1295